Last reviewed · How we verify
Rituximab and Hyaluronidase Human
Rituximab targets CD20 on B cells to deplete them, while hyaluronidase enables subcutaneous delivery by breaking down hyaluronic acid in subcutaneous tissue.
Rituximab targets CD20 on B cells to deplete them, while hyaluronidase enables subcutaneous delivery by breaking down hyaluronic acid in subcutaneous tissue. Used for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis.
At a glance
| Generic name | Rituximab and Hyaluronidase Human |
|---|---|
| Also known as | Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Rituxan Hycela, |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | Monoclonal antibody with recombinant human hyaluronidase |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Rituximab is a chimeric monoclonal antibody that binds CD20 antigen on B lymphocytes, leading to B-cell depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. The addition of human hyaluronidase allows for subcutaneous administration instead of intravenous infusion, improving patient convenience and potentially reducing infusion-related reactions.
Approved indications
- B-cell non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
- Rheumatoid arthritis
Common side effects
- Infusion-related reactions
- Infection
- Cytopenias
- Fatigue
- Injection site reactions
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma (PHASE3)
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission (PHASE3)
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (PHASE3)
- Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas (PHASE2)
- A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL (PHASE2)
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |